Chemist & Druggist is part of the Informa Tech Division of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission. Printed by #UserName#, #Company_Name#


Printed By

UsernamePublicRestriction

McKesson takes control of Celesio boardroom

Lloydspharmacy parent company Celesio has surrendered its top boardroom positions to McKesson, following its takeover by the US healthcare giant in January

Lloydspharmacy parent company Celesio has surrendered its top boardroom positions to McKesson, following its takeover by the US healthcare giant in January.


Marc Owen, president of McKesson's speciality health division, has been appointed chairman of Celesio's management board, the European pharmacy company announced yesterday (May 22).


McKesson senior vice president and chief financial officer Alain Vachon will take over from Marion Helmes as Celesio's chief financial officer, it said.


Marc Owen, president of McKesson's speciality health division, has been appointed chairman of Celesio's management board


More on Celesio

Lloydspharmacy performance lifts Celesio profits

Video: The strategy of Lloydspharmacy under Celesio

In depth: The United States of Celesio

Both changeovers will come into effect on July 16, when Ms Helmes will stand down as speaker of Celesio's management board - a position she has held since chief executive Markus Pinger was ousted from the board over a difference of opinion last year.


John H Hammergren, McKesson chief executive officer and chairman of Celesio's supervisory board, said Mr Owen was a "talented healthcare strategist".


"With his broad experience across all sectors of healthcare, combined with his deep knowledge of the European market, Marc is uniquely qualified to lead Celesio as it becomes part of McKesson," he said.


Last week, Celesio reported a 0.3 per cent revenue increase to £4.4 billion in the first quarter of 2014, which it attributed to a strong performance from Lloydspharmacy. The company forecast even stronger growth from 2015 through the "rapid realisation" of its European Pharmacy Network model, which will be opened up to independents later this year.


In January, McKesson confirmed it would buy Celesio, a week after both parties revealed the deal had fallen through due to the reluctance of Celesio shareholders to sell up.


The following month, Celesio UK managing director Cormac Tobin told C+D that the takeover by McKesson was unlikely to affect Lloydspharmacy's strategy.



What do the appointments say about the future of Celsio and Lloydspharmacy?

Comment below or email us at [email protected] You can also find C+D on Twitter, LinkedIn and Facebook

Topics

Pre-reg Trainee

Tonbridge, Kent

 Salary: £22,000

Apply Now
UsernamePublicRestriction

Register

CD017025

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel